Donepezil, Residual Excessive Daytime Sleepiness, Obstructive Sleep Apnea

• Status: Unknown status
• Trial end date: 2019-03-02
• Target enrollment: 0
• Participant gender: All

Summary

It is a randomized, double-blind, single-center, 30-day study. Patients aged 35-60 years, with apnea and hypopnea index and respiratory disturbance index normalized with CPAP, and Epworth Sleepiness Scale> 11. Patients undergo baseline and CPAP titration polysomnography, liquor and blood collection, Multiple Sleep Latency Test, anxiety and depression and cognitive assessments.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Associação Fundo de Incentivo à Pesquisa
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Both gender, Age between 35 and 65 years;

• Confirmed diagnosis of moderate to severe OSA;

• Treatment with CPAP for at least six months;

• Persistent sleepiness with daily CPAP use compliance > 5 hours per night.

Exclusion Criteria:

• Neurological or psychiatric diseases;

• Chronic use of psychoactive drugs, other sleep disorders than OSA, visual defficiency, illiteracy.